Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):964–970. doi: 10.1038/bjc.1996.466

Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers.

J L Pujol 1, J Simony 1, G Jolimoy 1, D Jaffuel 1, P Demoly 1, X Quantin 1, C Marty-Ané 1, J M Boher 1, R Charpentier 1, F B Michel 1
PMCID: PMC2074737  PMID: 8826867

Abstract

One hundred and thirty-seven lung cancer patients (123 non-small-cell lung cancers (NSCLC), 10 small-cell lung cancers (SCLC) and four carcinoid tumours) who underwent surgery in an attempt at complete resection were prospectively entered in a study whose aim was to determine the prognostic significance of a hypodiploidy or a multiploidy pattern of tumour cell DNA content and a high immunohistochemical reactivity of Ki-67, a nuclear antigen related to the cell cycle. Indirect immunoperoxidase reactivity of Ki-67 on frozen tumour tissue sections was evaluated both visually, using a classical semiquantitative scale, and by means of a computer-assisted image processor. Cell DNA content analysis was done using static computer-assisted cytometry on tumour cytological prints stained by the pararosaline Feulgen-Schiff technique. The ploidy was characterised for each tumour by DNA index (DI), percentage of hypodiploid cells and type of DNA content histogram (near diploid, hyperdiploid, hypodiploid and multiploid). Ki-67 immunostaining was negative in 64 tumours (48%) and positive in 69 (52%). DNA histogram classification disclosed 57 (42%) near diploid tumours. Among the 80 (58%) aneuploid tumours, 16 were hypodiploid, 44 hyperdiploid and 20 multiploid. The prevalence of both a positive Ki-67 immunostaining and an aneuploid DNA histogram differed according to histology as SCLC demonstrated a higher frequency of both features when compared with NSCLC and carcinoid tumours. On the other hand, Ki-67 immunostaining and ploidy did not significantly differ according to degree of differentiation, nodal status and Mountain's stage grouping. The percentage of cells in the hypodiploid modal DNA was significantly higher for tumours which demonstrated a high Ki-67 immunostaining, suggesting a link between growth fraction and DNA content abnormalities. In univariate analysis, survival did not differ significantly according to either the Ki-67 immunohistochemical reactivity or the DNA index. Patients with a hypodiploid tumour had a shorter survival than patients with other DNA histogram patterns but, owing to the low frequency of hypodiploidy, this difference did not reach statistical significance. In Cox's proportional hazard model, an SCLC histology, an advanced tumour status, a positive nodal status and a hypodiploid tumour (hazard ratio: 2.070; 95% confidence interval 1.041-4.116) were significant determinants of survival. We conclude that hypodiploidy in lung cancer is a distinct DNA content abnormality as it contributes significantly to prognosis. Neither visually assessed nor computer-generated Ki-67 immunostaining measurements significantly determine prognosis.

Full text

PDF
964

Images in this article

967Figure 2
on p.967

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe S., Makimura S., Itabashi K., Nagai T., Tsuneta Y., Kawakami Y. Prognostic significance of nuclear DNA content in small cell carcinoma of the lung. Cancer. 1985 Oct 15;56(8):2025–2030. doi: 10.1002/1097-0142(19851015)56:8<2025::aid-cncr2820560823>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  2. Barlogie B., Drewinko B., Schumann J., Göhde W., Dosik G., Latreille J., Johnston D. A., Freireich E. J. Cellular DNA content as a marker of neoplasia in man. Am J Med. 1980 Aug;69(2):195–203. doi: 10.1016/0002-9343(80)90379-4. [DOI] [PubMed] [Google Scholar]
  3. Barlogie B., Raber M. N., Schumann J., Johnson T. S., Drewinko B., Swartzendruber D. E., Göhde W., Andreeff M., Freireich E. J. Flow cytometry in clinical cancer research. Cancer Res. 1983 Sep;43(9):3982–3997. [PubMed] [Google Scholar]
  4. Blöndal T., Bengtsson A. Nuclear DNA measurements in squamous cell carcinoma of the lung: a guide for prognostic evaluation. Anticancer Res. 1981;1(2):79–86. [PubMed] [Google Scholar]
  5. Bunn P. A., Jr, Carney D. N., Gazdar A. F., Whang-Peng J., Matthews M. J. Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer. Cancer Res. 1983 Oct;43(10):5026–5032. [PubMed] [Google Scholar]
  6. Cheon S. H., Sohn H. Y., Chang J., Kim S. K., Ko E. H., Kim S. K., Lee W. Y., Lee D. Y., Shin D. H., Jeong E. T. Flow cytometric analysis of DNA ploidy in primary non-small cell carcinoma of the lung in Korea. Yonsei Med J. 1993 Dec;34(4):365–370. doi: 10.3349/ymj.1993.34.4.365. [DOI] [PubMed] [Google Scholar]
  7. Cibas E. S., Melamed M. R., Zaman M. B., Kimmel M. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer. 1989 Apr 15;63(8):1552–1556. doi: 10.1002/1097-0142(19890415)63:8<1552::aid-cncr2820630817>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Coulson P. B., Thornthwaite J. T., Woolley T. W., Sugarbaker E. V., Seckinger D. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res. 1984 Sep;44(9):4187–4196. [PubMed] [Google Scholar]
  9. Dazzi H., Thatcher N., Hasleton P. S., Swindell R. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med. 1990 May;84(3):217–223. doi: 10.1016/s0954-6111(08)80038-8. [DOI] [PubMed] [Google Scholar]
  10. Friedlander M. L., Hedley D. W., Taylor I. W. Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol. 1984 Sep;37(9):961–974. doi: 10.1136/jcp.37.9.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  12. Gratzner H. G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science. 1982 Oct 29;218(4571):474–475. doi: 10.1126/science.7123245. [DOI] [PubMed] [Google Scholar]
  13. Hayashi Y., Fukayama M., Koike M., Kaseda S., Ikeda T., Yokoyama T. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn. 1993 Jun;43(6):313–319. doi: 10.1111/j.1440-1827.1993.tb02573.x. [DOI] [PubMed] [Google Scholar]
  14. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  15. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  16. Opfermann M., Brugal G., Vassilakos P. Cytometry of breast carcinoma: significance of ploïdy balance and proliferation index. Cytometry. 1987 Mar;8(2):217–224. doi: 10.1002/cyto.990080216. [DOI] [PubMed] [Google Scholar]
  17. Pence J. C., Kerns B. J., Dodge R. K., Iglehart J. D. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg. 1993 Dec;128(12):1382–1390. doi: 10.1001/archsurg.1993.01420240090017. [DOI] [PubMed] [Google Scholar]
  18. Salvati F., Teodori L., Gagliardi L., Signora M., Aquilini M., Storniello G. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications. Chest. 1989 Nov;96(5):1092–1098. doi: 10.1378/chest.96.5.1092. [DOI] [PubMed] [Google Scholar]
  19. Simony J., Pujol J. L., Radal M., Ursule E., Michel F. B., Pujol H. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res. 1990 Jul 15;50(14):4382–4387. [PubMed] [Google Scholar]
  20. Smith L., Barlogie B., Alexanian R. Biclonal and hypodiploid multiple myeloma. Am J Med. 1986 May;80(5):841–843. doi: 10.1016/0002-9343(86)90625-x. [DOI] [PubMed] [Google Scholar]
  21. Theunissen P. H., Leers M. P., Bollen E. C. Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology. 1992 Mar;20(3):251–255. doi: 10.1111/j.1365-2559.1992.tb00964.x. [DOI] [PubMed] [Google Scholar]
  22. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol. 1989 May;15(1):1–18. doi: 10.1016/0167-8140(89)90113-8. [DOI] [PubMed] [Google Scholar]
  23. Tungekar M. F., Gatter K. C., Dunnill M. S., Mason D. Y. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 1991 Dec;19(6):545–550. doi: 10.1111/j.1365-2559.1991.tb01503.x. [DOI] [PubMed] [Google Scholar]
  24. Volm M., Drings P., Mattern J., Sonka J., Vogt-Moykopf I., Wayss K. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer. 1985 Sep 15;56(6):1396–1403. doi: 10.1002/1097-0142(19850915)56:6<1396::aid-cncr2820560630>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  25. Zimmerman P. V., Hawson G. A., Bint M. H., Parsons P. G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet. 1987 Sep 5;2(8558):530–533. doi: 10.1016/s0140-6736(87)92923-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES